TIANXIN PHARMA(SH:603235) Shang Hai Zheng Quan Bao·2026-01-26 20:51Core Viewpoint - The announcement details the expected daily related transactions for Jiangxi Tianxin Pharmaceutical Co., Ltd. in 2026, emphasizing that these transactions will not affect the company's independence or financial stability [2][32]. Group 1: Daily Related Transactions Overview - The board of directors approved the expected daily related transactions for 2026 on January 26, 2026, with a voting result of 6 in favor and 0 against [2][4]. - The expected total amount for daily related transactions in 2026 is capped at 68.4725 million RMB [8]. - The transactions include services such as processing vitamin E powder and providing meeting services, as well as leasing properties for employee accommodation [8][31]. Group 2: Impact and Compliance - The independent directors reviewed the proposal on January 22, 2026, and unanimously agreed that the transactions align with the company's business development and do not harm the interests of shareholders, particularly minority shareholders [4][32]. - The company asserts that these transactions are normal business activities and are conducted at market prices, ensuring fairness and compliance with relevant laws and regulations [31][32]. Group 3: Related Parties - The related parties involved include Zhejiang Xinweishi Biotechnology Co., Ltd., Qi Shan Tiancheng Vinegar Industry Co., Ltd., and Shanghai Nuirui Biotechnology Co., Ltd., all of which are under the indirect control of the company's actual controller, Xu Jiangnan [10][11][13][14]. - The announcement provides detailed information about the related parties, including their registration details, capital structure, and business scope [10][11][13][14].